tirzepatide synergy nash liver fibrosis in the SYNERGY-NASH trial, researchers assessed the efficacy and safety of once-weekly Synergistic mechanisms of tirzepatide and – tirzepatide in nash Consistent improvements

The prize is awarded by a committee consisting of three members from the Novo Nordisk Foundations Committee on Endocrinology and Metabolism and the Chair of the Scandinavian Society for the Study of Diabetes

A., and Stella, A

Fras JP, Auerbach P, Bajaj HS et al (2021) Efficacy and safety of once-weekly semaglutide 20 mg versus 10 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial

It has a favorable safety profile, with most studies documenting minimal side effect rates, with tolerance comparable to placebo

Traditional GLP-1 treatments are typically administered through injections, which work quickly but wear off just as fast

Follow-up every three months thereafter